Law, Rebekah http://orcid.org/0000-0001-9248-605X
Krupa, Katherine
Rusby, Jennifer http://orcid.org/0000-0003-0967-1778
Funding for this research was provided by:
NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research
Article History
Received: 9 January 2023
Accepted: 24 May 2023
First Online: 19 June 2023
Declarations
:
: Rebekah Law: Nothing to declare. Katherine Krupa: Employment: Daiichi Sankyo/Lilly (Immediate Family Member). Stock and Other Ownership Interests: Pfizer (Immediate Family Member). Jennifer Rusby: Nothing to declare.
: The PIONEER study was granted Health Research Authority (HRA) ethical approval by the Westminster Ethics Committee. IRAS project ID 265619, ClinicalTrials.gov Identifier: NCT04574063.
: Appropriate informed consent was gained for participants joining the PIONEER study. Consent forms were reviewed and approved by HRA. All women found to have moderate or high breast cancer risk through the PIONEER study were offered an appointment with the preventative therapy clinic to fulfil the duty of care to women found to be at increased risk. Figures were created using Microsoft excel.